Lancet eClinicalMedicine
Consumers Taking GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study 76% of those who discontinued GLP-1s are eating the same amount or less and many report retaining healthy habits JACKSONVILLE, Fla., April 14, 2025 /PRNewswire/ -- In advance of the National Association of Chain Drug Stores (NACDS) Annual Meeting, Acosta Group is sharing the results of its recent proprietary GLP-1 Shopper Community study, focusing on consumers using the medications specifically to support weight loss
Track how you feel : Keeping a daily record of your mood alongside your dose, nutrition, and side effects helps you identify patterns and share concrete information with your care team
The effects of resveratrol in patients with cardiovascular disease and heart failure: A narrative review
Debido a sus mltiples mecanismos, produce prdida de peso importante, al mismo tiempo que se obtienen beneficios sobre los factores de riesgo cardiovascular
Genetic Predispositions in Peptide Pathways: Why Your DNA Influences Response Genetic variation in GLP-1 receptor (GLP1R rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) genes affects appetite regulation, baseline metabolic rate, and medication response
